Publications

G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program.

Authors: F Antignano, M Braam, MR Hughes, AL Chenery, K Burrows, MJ Gold, MJ Oudhoff...

Research group: Halim Group

E-pub date: 27 Jun 2016

Journal name: J Exp Med

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

Authors: B Pereira, S-F Chin, OM Rueda, H-KM Vollan, E Provenzano, HA Bardwell, M Pu...

Research group: Rosenfeld Group

E-pub date: 6 Jun 2016

Journal name: Nat Commun

DNA REPAIR. Drugging DNA repair.

Authors: SP Jackson, T Helleday

Research group: Jackson Group

E-pub date: 3 Jun 2016

Journal name: Science

OC-053 Lectin-Based Near infra-red Molecular Imaging for Dysplasia Detection in Barrett’s Oesophagus: An ex-vivo Study on Human Tissue

Authors: M Di Pietro, A Neves, M O’Donovan, D Waterhouse, S Bohndiek, K Brindle, R...

Research group: Brindle Group

E-pub date: 1 Jun 2016

Journal name: Gut

PTU-085 A NOTCH1-Driven Secretome Switch Modulates Immune Surveillance In Ras-Induced Senescence

Authors: M Hoare, Y Ito, T-W Kang, S Menon, R Salama, L Zender, M Narita

Research group: Narita Group

E-pub date: 1 Jun 2016

Journal name: Gut

DIFFERENTIAL RESPONSES OF MURINE MODELS OF SUPRATENTORIAL EPENDYMOMA TO GEMCITABINE AS MEASURED BY MRI AND PET-CT

Authors: N Boulos, J Kim, Z Patay, ER Butch, M Ayaz, SE Snyder, C Calabrese, RJ Gilb...

Research group: Gilbertson Group

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES – AN EXAMPLE OF BRAIN TUMOUR THERAPY

Authors: B Nimmervoll, Y Patel, B Bianski, M DeCuypere, A Shelat, C Stewart, T Merch...

Research group: Gilbertson Group

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS

Authors: Y Tong, D Merino, B Nimmervoll, K Gupta, D Finkelstein, DW Ellison, J Zang,...

Research group: Gilbertson Group

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

Filters

Research Groups

Core Facilities

Start date

End date

G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

DNA REPAIR. Drugging DNA repair.

OC-053 Lectin-Based Near infra-red Molecular Imaging for Dysplasia Detection in Barrett’s Oesophagus: An ex-vivo Study on Human Tissue

PTU-085 A NOTCH1-Driven Secretome Switch Modulates Immune Surveillance In Ras-Induced Senescence

DIFFERENTIAL RESPONSES OF MURINE MODELS OF SUPRATENTORIAL EPENDYMOMA TO GEMCITABINE AS MEASURED BY MRI AND PET-CT

A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES – AN EXAMPLE OF BRAIN TUMOUR THERAPY

NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS

Themes

Filters

Research Groups

Core Facilities

Start date

End date

G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

DNA REPAIR. Drugging DNA repair.

OC-053 Lectin-Based Near infra-red Molecular Imaging for Dysplasia Detection in Barrett’s Oesophagus: An ex-vivo Study on Human Tissue

PTU-085 A NOTCH1-Driven Secretome Switch Modulates Immune Surveillance In Ras-Induced Senescence

DIFFERENTIAL RESPONSES OF MURINE MODELS OF SUPRATENTORIAL EPENDYMOMA TO GEMCITABINE AS MEASURED BY MRI AND PET-CT

A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES – AN EXAMPLE OF BRAIN TUMOUR THERAPY

NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS